TABLE 4.

Evaluation for synergy of combinations consisting of TOB-CIP and mitomycin C against MDR clinical isolates of P. aeruginosa and A. baumannii.

Organism	MICMitomycin C [MICcombo], μg/mL	MICTOB–CIP [MICcombo], μg/mL	FIC index	Interpretation	Absolute MICMitomycin C,a μg/mL	Fold potentiationb
P. aeruginosa PA259-96918	2 [0.25]	128 [8]	0.187	Synergy	0.5	4-fold
P. aeruginosa PA260-97103	2 [0.031]	16 [2]	0.141	Synergy	0.016	128-fold
P. aeruginosa PA262-101856	2 [0.25]	256 [16]	0.187	Synergy	0.5	4-fold
P. aeruginosa PA264-104354	2 [0.125]	64 [8]	0.187	Synergy	0.25	8-fold
P. aeruginosa 100036	4 [0.25]	64 [4]	0.125	Synergy	0.25	16-fold
A. baumannii AB027	32 [8]	>128 [2]	0.250 < × < 0.266	Synergy	8	4-fold
A. baumannii AB031	32 [8]	128 [16]	0.375	Synergy	16	2-fold
A. baumannii 92247	8 [2]	64 [32]	0.750	Additive	8	1-fold
A. baumannii LAC-4	8 [1]	>128 [16]	0.125 < × < 0.250	Synergy	2	4-fold

^aMIC of mitomycin C in the presence of 4 μg/mL TOB-CIP. ^bFold potentiation of mitomycin C in the presence of 4 μg/mL TOB-CIP.